Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | MITF | O75030 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142315 | 1.00 | KMT2A (0.71) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL8571158 | 0.93 | RAB9A (0.62) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL8572381 | 0.92 | KMT2A (0.83) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL9134339 | 0.92 | KMT2A (0.83) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL23898948 | 0.92 | KMT2A (0.83) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL20764540 | 0.87 | KMT2A (0.71) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL16367722 | 0.87 | KMT2A (0.76) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL24213121 | 0.87 | KMT2A (0.76) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL674700 | 0.85 | KMT2A (0.73) | KMT2ARAB9AMEN1NPC1MITF | |
| SCHEMBL7696438 | 0.85 | KMT2A (0.79) | KMT2ARAB9AMEN1NPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912563-B | Benzo five-membered nitrogen heterocyclic compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-05-27 | — | — | CN | disclosed |
| US-20230219925-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219925-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219925-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2022007168-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 中国科学院广州生物医药与健康研究院 | 2022-01-13 | — | — | WO | disclosed |
| CN-113912563-A | Benzo five-membered nitrogen heterocyclic compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-01-11 | — | — | CN | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| CN-105916841-A | Functionalised and substituted indoles as anti-cancer agents | 诺沃根公司 | 2016-08-31 | — | — | CN | disclosed |
| US-9187467-B2 | 2-phenyl benzothiazole linked imidazole compounds as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-17 | — | — | US | disclosed |
| US-20150141657-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-05-21 | — | — | US | disclosed |
| EP-2556072-B1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2014-05-21 | — | — | EP | disclosed |
| EP-2556072-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2012110959-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-23 | — | — | WO | disclosed |
| US-5728835-A | HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS | TOA EIYO, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0661266-A1 | Substituted cyclic amine compounds as 5HT2 antagonists | TOA EIYO LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | KMT2A 2215/4885RAB9A 3741/4885MEN1 3325/4885 |
| US-20150141657-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NFE2L2, TPT1, CCNT1 | KMT2A 305/4885RAB9A 2123/4885MEN1 2781/4885 |
| US-20230219925-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | RORC, RORB, RORA | KMT2A 3561/4885RAB9A 3032/4885MEN1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.